Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Cantor Fitzgerald Maintains Neutral on HEXO, Raises Price Target to C$3.45

Cantor Fitzgerald analyst Pablo Zuanic maintains HEXO (TSX:HEXO) with a Neutral and raises the price target from C$3.4 to C$3.45.

byvishwanath@benzinga.com

August 31, 2021

1 minute read

Cantor Fitzgerald analyst Pablo Zuanic maintains HEXO (TSX:HEXO) with a Neutral and raises the price target from C$3.4 to C$3.45.

Piper Sandler Initiates Coverage On Microvast Holdings with Neutral Rating, Announces Price Target of $8

By Benzinga Newsdesk

Today, 3:35 AM

Piper Sandler analyst Greg Tuttle initiates coverage on Microvast Holdings (NASDAQ:MVST) with a Neutral rating and announces Price Target of $8.

MVST

Delta Air Lines, Msci And This Japanese Stock On CNBC’s ‘Final Trades’

By Priya Nigam

Today, 3:35 AM

On CNBC’s "Halftime Report Final Trades," Amy Raskin of Chevy Chase Trust named Fanuc ADR (OTC: FANUY), which is the no. 1 global manufacturer of industrial robots.

DAL

Telsey Advisory Group Reiterates Outperform on Coursera, Maintains $20 Price Target

By Benzinga Newsdesk

Today, 3:35 AM

Telsey Advisory Group analyst Sarang Vora reiterates Coursera (NYSE:COUR) with a Outperform and maintains $20 price target.

COUR

Bluebird bio’s Neurodegenerative Disease Gene Therapy Under Priority FDA Review, Despite Clinical Hold

By Vandana Singh

Today, 3:35 AM

The

BLUE

Cantor Fitzgerald Maintains Neutral on HEXO, Raises Price Target to C$3.45

Related Posts

Piper Sandler Initiates Coverage On Microvast Holdings with Neutral Rating, Announces Price Target of $8

Delta Air Lines, Msci And This Japanese Stock On CNBC’s ‘Final Trades’

Telsey Advisory Group Reiterates Outperform on Coursera, Maintains $20 Price Target

Bluebird bio’s Neurodegenerative Disease Gene Therapy Under Priority FDA Review, Despite Clinical Hold